358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer

Authors :: Donna M. Fitzgerald
Jeffrey Peppercorn
AH Partridge
Heather A. Parsons
Sara M. Tolaney
Irene Kuter
Jennifer A. Ligibel
Dejan Juric
Paula D. Ryan
Elene Viscosi
V. Attaya
Laura Spring
M. Shellock
Aditya Bardia
Beverly Moy
B. Lormill
D. Chawla
Leif W. Ellisen
Source :: Annals of Oncology. 31:S394
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Antibody-drug conjugate
business.industry
Hematology
chemistry.chemical_compound
Oncology
chemistry
Phase (matter)
PARP inhibitor
Sacituzumab govitecan
Cancer research
Medicine
Talazoparib
business
Triple-negative breast cancer

Tools